For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project
Tokyo, Japan (October 29, 2012) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project. The researchers were selected from universities and public research centers in Japan. Daiichi Sankyo will soon begin signing agreements with the selected parties to initiate collaborative research.
1. Total entries: 250
2. Selected parties: 20
3. Selections by entry type
|
|
Entries
|
Those that passed second selection
|
Final selections
|
| A. Theme/technology discovery |
220
|
24
|
16
|
| B. Theme/technology development |
17
|
3
|
1
|
| C. Pharmaceutical technology development |
13
|
3
|
3
|
|
Total
|
250
|
30
|
20
|
4. Selections by research theme
|
|
Entries
|
Those that passed second selection
|
Final selection
|
|
Oncology
|
103
|
7
|
4
|
|
Cardiovascular metabolics
|
71
|
8
|
3
|
|
Leading edge pharmaceuticals
|
58
|
3
|
3
|
|
Antibodies
|
41
|
8
|
5
|
|
Nucleic acid therapeutics, peptide pharmaceuticals, DDS
|
66
|
4
|
2
|
|
Pharmaceutical technology platforms
|
17
|
3
|
3
|
|
Total
(Entries with multiple themes are counted once for each theme)
|
356
|
33
|
20
|
For more information about the TaNeDS program visit the Daiichi Sankyo corporate website:
https://www.daiichisankyo.co.jp/rd/taneds/index.html (Japanese only)
End